Johnston Erwin, TRexBio CEO
Exclusive: Eli Lilly boosts inflammatory disease pipeline, licenses three candidates from TRexBio
Eli Lilly is adding three new preclinical candidates to its immune and inflammatory medicines armory through TRexBio, a Bay Area biotech that specializes in T …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.